



SVB Securities Serves as Financial Advisor to Lantheus (NASDAQ: LNTN) on its Exclusive Licensing Agreements with Point Biopharma (NASDAQ: PNT)

Key Transaction Highlights

- On November 14, 2022, Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTN) and POINT Biopharma Global Inc. ("POINT") (NASDAQ: PNT) announced a set of strategic collaboration agreements in which Lantheus will license exclusive worldwide rights to POINT's PNT2002 and PNT2003 product candidates
- The agreements expand Lantheus' radiopharmaceutical portfolio with two late-stage therapeutic candidates and, with PNT2002, broadens Lantheus' prostate cancer franchise
- For POINT, the agreement pairs PNT2002 and PNT2003 with an ideal commercialization partner, and offsets launch and marketing risks, while still maintaining the value and independence of POINT's next generation radioligand platform
- PNT2002 is a PSMA-targeted ¹⁷⁷Lu-based radiopharmaceutical therapy for metastatic castration-resistant prostate cancer (mCRPC) and currently in its Phase 3 SPLASH study
- PNT2003 is a somatostatin receptor (SSTR) targeted radioligand therapy with no-carrier-added ¹⁷⁷Lu in development for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and currently in its Phase 3 OZM-067 study

About Lantheus

With more than 65 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden.

About Point Biopharma

POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT aims to transform precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 (225Ac) and lutetium-177 (177Lu). POINT's active clinical trials include FRONTIER, the Phase 1 trial for PNT2004, a pan-cancer program targeting fibroblast activation protein-α (FAP-α), and SPLASH, the Phase 3 trial for PNT2002 for people with metastatic castration resistant prostate cancer (mCRPC) after second-line hormonal treatment.

If you would like to unsubscribe from this distribution, click [here](#). If you would like to unsubscribe from all SVB Securities distributions, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
227 West Trade Street
Suite 2050
Charlotte, NC 28202

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111